fda warning glp-1 compounding september 2025 The Skinny on Emerging Exposures for the Healthcare Industry BREAKING NEWS in the compounding

W., Hankosky, E

Hardin BD, Kelman BJ, Saxon A

Their use in these populations has been associated with hemoglobin A1c reduction, significant weight loss, and a decrease in long-term microvascular and macrovascular complications ( This mini-review discusses clinical studies evaluating adjuvant treatment with GLP-1RA in patients with T1D as an opportunity to improve glycemic control, achieve weight loss, and decrease total daily insulin (TDI) requirements in these patients

Now, at 128 lbs (58.1 kg), theyve flipped that on its head

Occludin KO mice develop chronic inflammation and hyperplasia despite normal mucosal barrier properties The occludin KO mice represented the first in vivo experimental strategy to directly manipulate a TJ protein

Notably, a Medicare GLP-1 Bridge pilot begins July 1, 2026 with a $50 monthly copay for eligible enrollees a change from the old rule that Medicare never covered weight loss drugs